PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Nov 16, 2017

byncaipen

Biomanufacturing

The Effects of ProtoKinetix' Anti-Aging Glycopeptide (AAGP®) on Immune Cell Banking and Functions Relevant to Immunotherapy

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update on immune cell banking and functions relevant to immunotherapy using AAGP® in collaboration...Read more

Oct 17, 2017

byncaipen

Biomanufacturing | Transplants

Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery

Belpre, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.